Boulder-based Think Bioscience has raised $55 million in an oversubscribed Series A funding round led by Regeneron Ventures, Innovation Endeavors and Janus Henderson Investors. Think Bio develops small molecule drugs for historically challenging drug targets
The company will advance its lead program intended to target the genetic condition Noonan syndrome, which does not yet have any approved therapies. Affecting one in 2,500 births, Noonan causes chronic symptoms including cardiac and lymphatic issues, short stature, cognitive impairment and pain.
Think Bio’s synthetic biology platform uses high-throughput functional surveys to advance small molecules with biochemical activities that have historically been difficult to achieve. Its platform addresses targets like transcription factors while advancing the company’s internal pipeline.
